About this Journal Submit a Manuscript Table of Contents
Sarcoma
Volume 2012 (2012), Article ID 126906, 11 pages
http://dx.doi.org/10.1155/2012/126906
Research Article

Enhanced Growth Inhibition of Osteosarcoma by Cytotoxic Polymerized Liposomal Nanoparticles Targeting the Alcam Cell Surface Receptor

1Division of Pediatric Hematology/Oncology, Department of Pediatrics, Mattel Children's Hospital and Gwynne Hazen Cherry Memorial Laboratories, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095-1781, USA
2NanoValent Pharmaceuticals Inc., Bozeman, MT 59718-4012, USA
3Department of Biomathematics, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095-1766, USA
4Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, UCLA, Los Angeles, CA 90095-1770, USA
5Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA 90027, USA
6Department of Anesthesia and Perioperative Cave, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94110, USA

Received 5 June 2012; Accepted 3 July 2012

Academic Editor: Norman Jaffe

Copyright © 2012 Noah Federman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. G. Huvos, Bone Tumors: Diagnosis, Treatment, and Prognosis, WB Saunders, Philadelphia, Pa, USA, 1991.
  2. D. C. Dahlin and K. K. Unni, “Osteosarcoma of bone and its important recognizable varieties,” American Journal of Surgical Pathology, vol. 1, no. 1, pp. 61–72, 1977. View at Scopus
  3. J. G. Gurney, A. R. Swensen, and M. Bulterys, “Malignant bone tumors,” in Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975–1995, pp. 99–110, SEER program, National Cancer Institute, Bethesda, Md, USA, 1999.
  4. K. A. Janeway and H. E. Grier, “Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects,” The Lancet Oncology, vol. 11, no. 7, pp. 670–678, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Puri, K. Loomis, B. Smith et al., “Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic,” Critical Reviews in Therapeutic Drug Carrier Systems, vol. 26, no. 6, pp. 523–580, 2009. View at Scopus
  6. L. H. Lindner and M. Hossann, “Factors affecting drug release from liposomes,” Current Opinion in Drug Discovery and Development, vol. 13, no. 1, pp. 111–123, 2010. View at Scopus
  7. T. L. Andresen, S. S. Jensen, and K. Jørgensen, “Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release,” Progress in Lipid Research, vol. 44, no. 1, pp. 68–97, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. T. M. Allen, “Ligand-targeted therapeutics in anticancer therapy,” Nature Reviews Cancer, vol. 2, no. 10, pp. 750–763, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. G. W. M. Swart, “Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration,” European Journal of Cell Biology, vol. 81, no. 6, pp. 313–321, 2002. View at Scopus
  10. S. F. Ofori-Acquah and J. A. King, “Activated leukocyte cell adhesion molecule: a new paradox in cancer,” Translational Research, vol. 151, no. 3, pp. 122–128, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Kristiansen, C. Pilarsky, C. Wissmann et al., “ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions,” Prostate, vol. 54, no. 1, pp. 34–43, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. J. A. King, S. F. Ofori-Acquah, T. Stevens, A. B. Al-Mehdi, O. Fodstad, and W. G. Jiang, “Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator,” Breast Cancer Research, vol. 6, no. 5, pp. R478–R487, 2004. View at Scopus
  13. B. Liu, A. Roth, D. C. Drummond et al., “Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells,” Molecular Cancer Therapeutics, vol. 6, no. 10, pp. 2737–2746, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. R. E. Bruehl, F. Dasgupta, T. R. Katsumoto et al., “Polymerized liposome assemblies: bifunctional macromolecular selectin inhibitors mimicking physiological selectin ligands,” Biochemistry, vol. 40, no. 20, pp. 5964–5974, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. J. M. D. T. Nelissen, R. Torensma, M. Pluyter et al., “Molecular analysis of the hematopoiesis supporting osteoblastic cell line U2-OS,” Experimental Hematology, vol. 28, no. 4, pp. 422–432, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Olmsted and M. Strand, “Fluorescence of polymerized diacetylene bilayer films,” Journal of Physical Chemistry, vol. 87, no. 24, pp. 4790–4792, 1983. View at Scopus
  17. H. Eckhardt, D. S. Boudreaux, and R. R. Chance, “Effects of substituent-induced strain on the electronic structure of polydiacetylenes,” The Journal of Chemical Physics, vol. 85, no. 7, pp. 4116–4119, 1986. View at Scopus
  18. B. Liu, F. Conrad, A. Roth, D. C. Drummond, J. P. Simko, and J. D. Marks, “Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer,” Journal of Molecular Medicine, vol. 85, no. 10, pp. 1113–1123, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. K. E. McCabe, B. Liu, J. D. Marks, J. S. Tomlinson, H. Wu, and A. M. Wu, “An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors,” Molecular Imaging and Biology, vol. 14, no. 3, pp. 336–347, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Barat, S. J. Sirk, K. E. McCabe et al., “Cys-diabody quantum dot conjugates (ImmunoQdots) for cancer marker detection,” Bioconjugate Chemistry, vol. 20, no. 8, pp. 1474–1481, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Haran, R. Cohen, L. K. Bar, and Y. Barenholz, “Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases,” Biochimica et Biophysica Acta, vol. 1151, no. 2, pp. 201–215, 1993.
  22. T. Ishida, M. J. Kirchmeier, E. H. Moase, S. Zalipsky, and T. M. Allen, “Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells,” Biochimica et Biophysica Acta, vol. 1515, no. 2, pp. 144–158, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. M. A. Bowen and A. Aruffo, “Adhesion molecules, their receptors, and their regulation: analysis of CD6-activated leukocyte cell adhesion molecule (ALCAM/CD166) interactions,” Transplantation Proceedings, vol. 31, no. 1-2, pp. 795–796, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. L. C. L. T. van Kempen, J. J. van den Oord, G. N. P. van Muijen, U. H. Weidle, H. P. J. Bloemers, and G. W. M. Swart, “Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin,” American Journal of Pathology, vol. 156, no. 3, pp. 769–774, 2000. View at Scopus
  25. E. C. M. Cabral, P. T. Hennies, C. R. D. Correia, R. L. Zollner, and M. H. A. Santana, “Preparation and characterization of diacetylene polymerized liposomes for detection of autoantibodies,” Journal of Liposome Research, vol. 13, no. 3-4, pp. 199–211, 2003. View at Scopus
  26. D. A. Sipkins, D. A. Cheresh, M. R. Kazemi, L. M. Nevin, M. D. Bednarski, and K. C. P. Li, “Detection of tumor angiogenesis in vivo by α(v)β3-targeted magnetic resonance imaging,” Nature Medicine, vol. 4, no. 5, pp. 623–626, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Guo, S. Liu, Z. Dai, C. Jiang, and W. Y. Li, “Polydiacetylene vesicles as a novel drug sustained-release system,” Colloids and Surfaces B, vol. 76, no. 1, pp. 362–365, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Puri, A. Yavlovich, A. Singh, and R. Blumenthal, “A novel class of photo-triggerable liposomes containing DPPC:DC 8,9PC as vehicles for delivery of doxorubcin to cells,” Biochimica et Biophysica Acta, vol. 1808, no. 1, pp. 117–126, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. Z. Li, G. T. Qin, R. M. Xia et al., “Partially polymerized liposomes: stable against leakage yet capable of instantaneous release for remote controlled drug delivery,” Nanotechnology, vol. 22, no. 15, Article ID 155605, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. D. E. L. de Menezes, M. J. Kirchmeier, J. F. Gagne, L. M. Pilarski, and T. M. Allen, “Cellular trafficking and cytotoxicity of anti-CD19-targeted liposomal doxorubicin in B lymphoma cells,” Journal of Liposome Research, vol. 9, no. 2, pp. 199–228, 1999. View at Scopus
  31. J. M. Moran-Mirabal, D. M. Aubrecht, and H. G. Craighead, “Phase separation and fractal domain formation in phospholipid/diacetylene-supported lipid bilayers,” Langmuir, vol. 23, no. 21, pp. 10661–10671, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. C. M. F. Gomes, H. van Paassen, S. Romeo et al., “Multidrug resistance mediated by ABC transporters in osteosarcoma cell lines: mRNA analysis and functional radiotracer studies,” Nuclear Medicine and Biology, vol. 33, no. 7, pp. 831–840, 2006. View at Publisher · View at Google Scholar · View at Scopus